drugset / Trial / NCT04515043
EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754)
NaSingle-groupOpen-labelOther
Summary
This study will be an exploratory study of long term immunogenicity of INVAC-1 in patients who participated in the INVAC1-CT-101 phase I study (between 2014 and 2018).
Timeline
- Start
- 2020-10-16
- Primary completion
- 2020-12-19
- Completion
- 2020-12-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INVAC-1, A DOUBLE STRANDED DNA PLASMID VACCINE CONSTRUCT ENCODING UBIQUITIN-HUMAN TELOMERASE REVERSE TRANSCRIPTASE (HTERT) FUSION PROTEIN | Vaccine | — | — |